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Abstract
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a major class of
natural products with a high degree of structural diversity and a wide variety of bioactivities.
Understanding the biosynthetic machinery of these RiPPs will benefit the discovery and
development of new molecules with potential pharmaceutical applications. In this review, we
discuss the features of the biosynthetic pathways to different RiPP classes, and propose
mechanisms regarding recognition of the precursor peptide by the posttranslational modification
enzymes. We propose that the leader peptides function as allosteric regulators that bind the active
form of the biosynthetic enzymes in a conformational selection process. We also speculate how
enzymes that generate polycyclic products of defined topologies may have been selected for
during evolution.
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Introduction
Natural products have played prominent roles in science and medicine over the past century.
The complex and diverse chemical scaffolds of natural products have inspired organic
chemists to devise new methodologies and new strategies for total synthesis,[1] their
biological activities have served as tools in cell biology,[2] and they have been important
lead compounds for development of new pharmaceuticals.[3]
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are natural
products that have only recently been recognized as a major class of compounds as a result
of the genome sequencing efforts of the past decade.[4] Because of their extensive
posttranslational modifications (PTMs), RiPPs have greater structural diversity and more
rigid structures compared to linear peptides,[5] and the PTMs endow them with expanded
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RiPP biosynthesis is initiated with a ribosomally generated precursor peptide encoded by a
structural gene. This precursor peptide usually contains an N-terminal leader peptide (Figure
1) that is important for recognition by PTM enzymes and for export from the cell. This
leader sequence is fused to a core peptide that is transformed into the final natural product.
In some cases a C-terminal recognition sequence (RS) that is important for excision and
cyclization of the core peptide is also present (Figure 1). Upon binding of the precursor
peptide to the modifying enzyme, various post-translational modifications are installed in
the core peptide. The leader peptide is usually removed by proteolytic cleavage in a late step
of the maturation process, which yields the final natural product.
This review will discuss new insights into the roles of the leader and core peptides during
post-translational modification of bacterial RiPPs.
Overview of RiPP Structures
Leader peptides have been proposed to play multiple roles during RiPP biosynthesis,
including acting as a secretion signal, a recognition motif for the PTM enzymes, a
chaperone-like sequence that assists precursor peptide folding and stabilization, or a
protective sequence that keeps the precursor peptide inactive inside the host until secretion
and proteolysis.[6] Among these potential roles, the recognition and modification of the
precursor sequence by the biosynthetic machinery is of particular interest. A better
understanding of this process will benefit the engineering of RiPP natural products, which
could potentially lead to increased biological activity and/or stability. Although at present
the molecular details of the interaction of the peptide substrates with the PTM machinery are
still mostly unknown, reports published in recent years have started to provide insights into
the mechanism(s) of leader peptide recognition and enzyme activation. In the next sections,
we will briefly present the PTMs of the RiPP classes produced by bacteria for which
information on leader peptide recognition is available or that have unusual leader peptides.
For other RiPP classes, such as the thiopeptides and glycopeptides as well as RiPPs from
higher organisms, we refer to a recent comprehensive review.[4] Subsequently, we will
address five questions: 1) is the leader peptide always required for the activity of the
biosynthetic enzymes, 2) how does leader peptide binding activate these enzymes, 3) how do
the biosynthetic enzymes recognize the leader peptide, 4) do the biosynthetic enzymes also
recognize the core peptide sequences, and 5) how can one enzyme make rings of different
sizes, sequences, and even stereochemistry?
Lanthipeptides
Lanthipeptides are a large group of polycyclic RiPPs classified by their intramolecular
thioether crosslinks named lanthionine (Lan) and methyllanthionine (MeLan) (Figure 2A).[7]
Lanthipeptides with antimicrobial activities are called lantibiotics.[8] The polycyclic
structure of lantibiotics constrains the conformational flexibility of the peptides, thereby
conferring improved affinity for their targets, which thus far have been small molecules
rather than macromolecules. One well-studied example is nisin produced by certain strains
of Lactococcus lactis, which possesses high antimicrobial potency against a wide range of
gram-positive bacteria (Figure 2B). This natural product contains five thioether rings formed
by one Lan and four MeLan residues[9] that are critical for its antimicrobial activity.[10]
The installation of the thioether residues in lanthipeptides is achieved in a two-step process:
dehydration of Ser/Thr residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb), and
stereoselective intramolecular addition of Cys thiols to the resulting dehydro amino acids
(Figure 2). The lanthipeptides are categorized into four classes according to the types of
(Me)Lan synthetases.[7f] Class I lanthipeptides, including nisin, utilize a dehydratase (LanB)
and a cyclase (LanC) to generate (Me)Lan residues (Figure 2B); Class II lanthipeptides use a
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single bifunctional synthetase (LanM).[11] Most of the well-studied lanthipeptides discussed
in this review belong to these two classes. The other two more recently discovered classes
(III and IV) both feature trifunctional synthetases that contain an N-terminal phospholyase
domain, a central kinase domain, and a C-terminal cyclase domain.[12] Interestingly, a
subset of the class III synthetases produce unique carbocyclic labionin residues (Figure
2A).[13] After the introduction of the thioether crosslinks, the modified core peptide is
typically exported from the producing cell through an ABC transporter (LanT), and the
leader peptide is cleaved by a protease LanP (class I lanthipeptides) or the protease domain
of LanT (class II lanthipeptides).[14]
Lasso peptides
Lasso peptides are characterized by a unique structure that assembles a threaded lasso
(Figure 3).[15] These peptides usually consist of 16-21 residues in which the N-terminal
amine and the side chain carboxylate of a Glu/Asp residue at position 8 or 9 form a
macrolactam, through which the C-terminal peptide tail is threaded. In class I and class III
lasso peptides, this constrained lasso structure is reinforced by one (class III) or two (class I)
additional disulfide bonds that connect the lasso ring to the peptide tail, whereas in class II
lasso peptides, bulky residues are often located close to the lasso that sterically lock the
threaded conformation (Figure 3B).[16] Structural analysis has also revealed that the lasso
rings of all tested peptides wrap their tail portion in a right-handed conformation (Figure
3C).[15] This unique structure provides lasso peptides with remarkable stability against
chemical and enzymatic degradation, and imparts diverse bioactivities.[15, 17] Disruption of
the lasso structure in microcin J25 (MccJ25) showed that it is a prerequisite for its
antimicrobial activity.[18]
Thus far, the biosynthetic machinery of lasso peptides is best understood for MccJ25[19] and
capistruin.[20] Using MccJ25 as a prototypical example, the mcjA gene encodes for a
precursor peptide that contains a 37-amino acid leader peptide and a 21-amino acid core
sequence. The McjB enzyme is an ATP-dependent cysteine protease[19a] that cleaves off the
leader sequence.[19c, 19d] The McjC enzyme is an Asn synthetase homolog[19b] that
adenylates the side chain carboxylic acid of Glu8 and catalyzes lactam formation.[19a-c] The
production of the correct lasso fold requires the presence of both McjB and McjC, indicating
that they are functionally interdependent.[19a, 19d] In the last step, the McjD enzyme, an
ABC transporter, is believed to export the final product from the cytoplasm.[19a, 19c]
Linear azol(in)e containing peptides
Linear azol(in)e containing peptides (LAPs) are non-macrocyclized RiPPs featuring multiple
thiazole and (methyl)oxazole heterocycles, and sometimes their corresponding 2-electron
reduced azolines (e.g. Figure 4), which conformationally constrain the peptide.[4, 21] LAP
family members exhibit various bioactivities, such as the DNA gyrase inhibitor microcin
B17,[22] the β hemolytic factor streptolysin S,[23] and the antibiotic plantazolicin.[24] The
thiazol(in)e and oxazol(in)e heterocycles are critical for the biological functions of the
LAPs.[21]
LAPs are generated from a precursor peptide comprised of a leader sequence and a core
peptide rich in residues with a β-nucleophile (Ser, Thr and Cys). Typically, a subset of these
residues are modified to form azol(in)e rings. The first step is the ATP-dependent
cyclodehydration of Ser, Thr, and Cys to produce azoline heterocycles by a
cyclodehydratase protein complex (C and D proteins).[22b, 25] Recent work has shown that
the D protein, a member of the YcaO/DUF181 protein family, is responsible for the
cyclodehydration reaction and uses ATP to phosphorylate the peptide backbone.[26] In the
second step, a subset or all of the azoline rings are oxidized to the aromatic azoles by a
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flavin-dependent dehydrogenase designated the B-protein.[22b, 27] Subsequently, the leader
peptide is proteolytically removed and the mature LAP is exported from the cell.
Cyanobactins
Cyanobacticins are a group of head-to-tail macrocyclized peptides produced by various
cyanobacteria, many of which are further modified with azol(in)e heterocycles and
prenylated Ser, Thr, or Tyr residues (Figure 5). These cyclic peptides have various
biological activities that have recently been reviewed.[28]
The cyanobactin precursor peptides contain a leader sequence and multiple cassettes that can
contain different core sequences.[29] In each cassette, the core sequence is sandwiched
between two flanking recognition sequences: a N-terminal protease recognition sequence
that typically consist of G(L/V)E(A/P)S, and a C-terminal recognition sequence that
contains AYDG(E).[30]
The first step is the generation of azol(in)e rings from Ser, Thr and Cys residues catalyzed
by the cyclodehydratase D (and the oxidase domain of another protein designated G), which
shares similarity with the LAP biosynthetic machinery.[22b, 29b, 31] Subsequently, a serine
protease (the A protein) removes the N-terminal recognition sequence, generating a free
amine. Next, a second serine protease (the G protein) recognizes the C-terminal recognition
sequence and removes it to form an acyl enzyme intermediate, that then is attacked by the
N-terminus of the peptide to achieve macrocyclization.[30, 32] Prenylation occurs after the
cyclization step, and it has been recently shown that the prenyltransferase only acts on the
cyclized peptide in the absence of the leader sequence.[33]
Bottromycins
Bottromycins represent a class of heavily modified RiPPs that contain unusual structures
including a macrocyclic amidine, a decarboxylated C-terminal thiazole, and multiple
carbon-methylated amino acids (Figure 6). Bottromycins and their derivatives exhibit potent
antimicrobial activity against bacterial pathogens such as methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).[34]
In contrast to other RiPPs characterized thus far, bottromycin does not have an N-terminal
leader peptide. Instead, a 37-residue sequence is attached to the C-terminus of the core
peptide as a follower sequence, which is believed to have a similar function to the leader
peptide.[35] Multiple radical S-adenosylmethionine (SAM) methyltransferases catalyze the
methylation of Pro, Phe and Val residues, while an O-methyltransferase is responsible for
the methylation of an Asp residue. Another two proteins with sequence similarity to the D-
protein in LAP biosynthesis are proposed to be involved in thiazoline formation, and
perhaps the macrocyclodehydration reaction that generates the amidine structure. Other
genes in the cluster encode several proteases and a cytochrome P450 enzyme that are likely
involved in removal of the N-terminal Met and the follower peptide, as well as oxidative
decarboxylation of the C-terminal residue.[35]
Microviridins
Microviridins are a class of N-acetylated polycyclic peptides mostly produced by
cyanobacteria. Microviridins are characterized by ester and amide crosslinks (Figure 7).
These lactone or lactam structures are formed between the carboxyl groups of Asp/Glu and
the hydroxyl groups of Ser/Thr, or with the amino groups of Lys, respectively.[36] The
precursor peptide of microviridins contains an N-terminal leader sequence and a C-terminal
core sequence. To date, the biosynthetic process has been partially elucidated.[37] The ester
and amide bonds are introduced by two classes of ATP grasp ligases in a strictly ordered
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process. The ester bonds are generated prior to amide formation, with the larger lactone
forming first and the smaller one forming second.[37c] After leader peptide removal,
acetylation of the N-terminus yields the mature microviridin.
Sactipeptides
Sactipeptides are characterized by thioether crosslinks, but unlike lanthipeptides, which have
thioether crosslinks between Cys and the β-carbon of formerly Ser and Thr residues, the
thioether bridges in sactipeptides are generated between cysteine and the α-carbon of a
variety of amino acids (Figure 8).[38] These thioether bridges fold the backbone of
sactipeptides into a hairpin-like structure. Structure determination has revealed that several
sactipeptides, such as subtilosin A,[38-39] thuricin CD,[40] and thuricin H,[41] possess an
amphipathic structure, which is likely responsible for their antimicrobial bioactivities.[41-42]
The precursor peptide of sactipeptides contains an N-terminal leader sequence. During the
biosynthesis, thioether bond formation is catalyzed by a radical SAM enzyme in a leader
peptide-dependent manner.[43]
Proteusins
Proteusins are a very recently classified RiPP family with polytheonamides as their first
characterized members.[4],[46a] Polytheonamides are extensively modified peptides
containing many unusual residues such as a novel N-acyl moiety, tert-leucines and other
carbon-methylated residues, as well as multiple D-configured amino acids that alternate with
L-amino acids throughout the peptide backbone (Figure 9).[44] Due to their unique structures
and strong hydrophobicity, polytheonamides are able to form helical structures that insert
into the cell membrane as single molecule channels.[45]
The precursor peptides possess a nitrile hydratase-like leader peptide (NHLP) or a Nif11
nitrogen fixing protein-like leader peptide (N11P).[46] The D-configured amino acids are
generated by the epimerase PoyD, and the Asn N-methylation is catalyzed by the SAM-
dependent methyltransferase PoyE.[46a] PoyF, which resembles the dehydratase domain of
the class II lanthipeptide synthetase, LanM, is responsible for the first step in generation of
the acylated N-terminus by dehydrating a Thr residue.[46a]
Role(s) of Leader and Core Peptides
Is the leader peptide always required for the biosynthetic enzymes?
The leader peptides play an important role in many but not all steps of RiPP biosynthesis.
With respect to the introduction of the characteristic PTMs of each compound class, the
leader peptide has been shown to be very important because deletion of the leader sequence
often results in reduced or abolished enzymatic formation of these PTMs.[6a] However,
many compound-specific posttranslational modifications have been shown not to require the
leader peptide. For instance, C-terminal decarboxylation,[47] hydroxylation,[48] and
oxygenation[49] in lanthipeptides, as well as prenylation of cyanobactins[33] takes place in
the absence of the leader peptide. Of course, most post-translational modification reactions
that require the free N-terminus of the core peptide (and hence take place after removal of
the leader peptide) also do not require the leader peptide such as head-to-tail cyclization of
cyanobactins[30, 32a, 32b] or N-terminal modifications in lanthipeptides.[50] In the remainder
of this review, we will only focus on the formation of the PTMs for which the leader peptide
has been shown to play a role.
How does leader peptide binding activate enzyme activity?
In one possible model, the leader peptide could induce some type of conformational change
to activate the biosynthetic enzymes for catalysis. Indeed, this model is supported by several
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experimental observations. For instance, a number of studies have illustrated that “random”
peptides attached to leader peptides are acted upon by the biosynthetic enzymes. In the case
of lanthipeptides, various non-natural peptides that were attached to the nisin leader peptide
could be dehydrated, cyclized and secreted by the nisin modification and export system in L.
lactis.[51] Examples included analogues of small therapeutic peptides with engineered
thioether rings,[52] and a randomized hexapeptide library with Dha/Dhb introduced at a fixed
position.[53] Similarly, the class II lanthionine synthetase LctM was shown to dehydrate and
cyclise non-lantibiotic peptides attached to the leader peptide of its substrate LctA.[54] Non-
natural cyclic peptides have also been generated by the cyclization machinery of
cyanobactins and lasso peptides by insertion of non-natural peptide sequence in pace of
native core peptides,[31],[55] and several RiPP biosynthetic enzymes have been shown to
accept chimeric peptides with the leader peptide of one compound and core peptide of
another (vide infra). These investigations show the very high substrate tolerance with respect
to the core peptide and seem to require a specific activation mechanism to prevent the
biosynthetic enzymes to act on just any peptide in the RiPP-producing cell.
More recently, an alternative model has been put forth in which the leader peptide does not
induce a conformational change in the biosynthetic enzymes but instead traps an active
conformation that is present in very small amounts in the absence of the leader peptide
(Figure 10). This alternative model was first introduced when it was observed that in vitro,
the lanthipeptide synthetase LctM that generates lacticin 481 (Figure 11) was able to very
slowly dehydrate the core peptide of its substrate LctA in the absence of a leader peptide. If
leader peptide binding were required to actively induce a productive conformation of the
LctM enzyme, no activity should have been observed. However, if a small concentration of
an active conformation of LctM were always present, it could explain a low basal level of
activity even in the absence of leader peptide. Support for such a model also operating inside
the producing organism is the recent observation that co-expression of just the core peptide
of the nisin precursor peptide NisA with the dehydratase NisB and the cyclase NisC in L.
lactis also results in a low level of posttranslational modification of the core peptide.[56]
The model in Figure 10 also explains the observations in several studies in which the leader
peptide was provided to the biosynthetic enzymes but was not covalently attached to the
core peptide. In trans addition of the leader and core peptides of the precursor LctA to LctM
resulted in dehydration in vitro that was enhanced compared to when the leader peptide was
absent.[57] Furthermore, increasing the concentration of the leader peptide resulted in
complete processing of the core peptide and the formation of bioactive lacticin 481 (for
structure, see Figure 11).[58] The most active system was obtained when the leader peptide
was fused to the LctM enzyme with a (GlySer)15 linker. This fusion enzyme was able to
convert the LctA core peptide into lacticin 481 with much improved efficiency, presumably
because of the increased effective concentration of the leader peptide.[58] The in trans
activation of the leader peptide for core peptide modification was also observed recently in a
study in which the leader and core peptides for nisin were co-expressed independently in a
L. lactis strain containing the NisB dehydratase and NisC cyclase.[56]
In trans activity has now been observed in the case of the class I lanthipeptide nisin,[56] class
II lanthipeptide lacticin 481,[57-58] and class III lanthipeptide catenulipeptin,[59] suggesting it
may be a general property of lanthipeptide synthetases.
Whether these observations will translate to all RiPP classes remains to be established. Most
investigations that have concluded that the leader peptides are absolutely indispensable have
been conducted in bacterial cells, and it may be that the amount of processing of core
peptides without leader peptides attached is so small that it has not been detected or that the
core peptides were not expressed or were degraded. A case in point is the observation that
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formation of the lasso peptide MccJ25 in E. coli requires the last eight residues of the leader
peptide[60] whereas a recent in vitro study concluded that a very low level of lasso peptide
formation occurs by incubation of just the core peptide with the two biosynthetic enzymes
McjB and McjC.[19d] The same study also demonstrated in vitro activity when the leader
and core peptides were provided in trans. In contrast, some in vitro reconstituted RiPP
biosynthetic systems did not display in trans activity such as the class III lanthipeptide
labyrinthopeptin A2[61] (Figure 11) and the LAP microcin B17 (Figure 4).[62] It is possible
that their biosynthetic enzymes are activated by the leader peptide in a different manner than
the model in Figure 10, or that perhaps the in vitro studies could not achieve sufficiently
high concentrations of the leader and core peptides to generate the required ternary complex.
Indeed, for many RiPPs the solubility of the precursor peptides is very poor and limits the
concentrations of core and leader peptides that can be attained.
The model in Figure 10 is consistent with many studies on conformational behaviour of
enzymes and their relationship to catalysis that have been reported over the past decade.[63]
These studies, which have utilized NMR methods to detect even very small concentrations
of different enzyme conformations within bulk populations, have provided an alternative to
the classical Koshland “induced fit” hypothesis. The latter is not unlike the model of leader
peptide binding inducing an active form of the PTM enzymes described above. In the more
recent “conformational selection” model,[63a] active and inactive protein conformations have
been observed to both exist in an ensemble, and a ligand, whether substrate or an allosteric
effector, selects the conformation that it has the highest affinity for. In doing so, substrate or
allosteric effectors can shift the distribution of conformations within the ensemble.[63a] The
proposed role of the leader peptide in Figure 10 is analogous. The leader peptide seeks out
the active form of the enzyme, which in the figure is arbitrarily shown as an open form but it
could also be a closed form with separate leader and core binding pockets.
Figure 10 also illustrates an additional possible role of the enzyme, which is that of a
pseudosubstrate or intrasteric regulator.[64] A pseudosubstrate is part of an enzyme that
resembles the substrate and that binds to the substrate binding site, thus keeping the
ensemble mostly composed of the inactive enzyme form. In the case of the RiPP
biosynthetic enzymes, the proteins could contain a domain (a “lid” domain) that docks onto
the leader peptide binding site in the absence of substrate, thus keeping the enzyme mostly
inactive. Because the binding affinity of the lid domain cannot be very tight (otherwise no
catalysis would be possible), a small population of the enzyme would have the lid open and
allow association of the leader peptide to its binding site. In turn, leader peptide binding
would then shift the equilibrium towards the active form of the PTM enzyme. We emphasize
that the model could be readily expanded to more complex models.[64b] For instance the
leader peptide of one substrate could serve as the allosteric effector for the core peptide of
another substrate, or the leader peptide could bind to the lid. We also note that the
biosynthetic enzymes other than the proteases do not necessarily strictly distinguish between
the parts of the precursor peptide we call the leader peptide and the core peptide, because
this distinction is only introduced after proteolysis. Hence, for some enzymes it is possible
that the binding site on the precursor peptide that activates a particular PTM enzyme by the
model in Figure 10 could span a stretch of amino acids that is on both leader peptide and
core peptide.
In addition to the two models presented thus far, in which the leader peptide binds in one
specific binding pocket, alternative mechanisms in which the leader peptide moves over or
through the enzyme have been proposed.[56] At present, no firm experimental support exists
for or against such a mechanism, except that several PTM enzymes do not require any
energy in the form of ATP,[59, 65] which appears to argue against any motor-like pulling on
the leader peptide. Further studies will be required to determine whether the leader peptide
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binds to one or multiple sites on each biosynthetic enzyme, and whether the same stretch of
amino acids on the leader peptide is involved (see also next section).
How do the biosynthetic enzymes recognize the leader peptide?
Whereas the model described in the previous section can account for many experimental
observations of how leader peptides might activate PTM enzymes of RiPP biosynthesis,
very little is understood regarding the exact molecular interactions that are involved in
leader peptide binding. At present, no crystal or NMR structures are available of any
enzyme in complex with the leader peptide. Perhaps the best understood systems are the
transporters that secrete substrates containing leader peptides that end in the double glycine
motif, and that also contain a protease domain that cleaves the leader peptide from the
modified core peptide. ComA, a transporter involved in cleavage and export of the quorum-
sensing signal precursor ComC in Streptococcus pneumonia has homology with the
transporters involved in RiPP biosynthesis. The leader peptide of ComC appears to attain a
helical conformation upon binding to ComA, but not in solution.[66] A crystal structure of
ComC showed that its protease active site is located at the end of a narrow cleft explaining
the selectivity for the double-glycine cleavage site.[67] The authors also identified a shallow
hydrophobic surface that was proposed to interact with the α-helical ComC leader peptide.
The residues making up this proposed binding site are conserved in many of the transporters
involved in RiPP biosynthesis.[67]
In the absence of any direct structural information, site-directed mutagenesis has been used
extensively to investigate the importance of specific residues in RiPP leader peptides.
Collectively, these studies have demonstrated that the biosynthetic enzymes generally
demonstrate very relaxed substrate specificity with respect to the leader peptides and that the
great majority of single mutations are well tolerated.[15, 68] Exceptions are the proteases that
remove the leader peptide, which as expected have a much lower tolerance for substitution
near the cleavage site.[14b, 68f, 69] It is possible that the generally observed plasticity with
respect to leader peptide mutations ensures high evolvability of the core peptide sequence
without loss of production as a consequence of leader peptide mutations. These studies have
also shown a propensity for helical structures of the leader peptides,[61-62, 68d, 68e, 70] which
is also supported by structure prediction programs. Most of these proposed helices are
amphiphilic. In many cases, however, a helical conformation is not observed in aqueous
buffer and secondary structure-inducing solvents such as trifluoroethanol are required to
obtain a helical structure.[61-62, 70a-c] The idea of an unstructured precursor peptide that folds
into a helical structure upon binding to their cognate biosynthetic enzymes is not without
precedent. Several recent studies have demonstrated that structurally disordered proteins
fold into defined structures upon binding their targets in the cell.[71] A general observation is
that leader peptides within each RiPP class are quite diverse but have some highly conserved
features and that most leader peptides have a preponderance of negatively charged
residues.[6]
In the case of lanthipeptides, in vivo and in vitro binding assays have shown a direct
interaction between the nisin leader sequence and the NisB/NisC enzymes.[72] The binding
interaction likely involves a conserved FNLD motif.[68f, 72] Leader peptide truncation for the
class II lanthipeptide lacticin 481 showed that the C-terminal portion of the leader sequence
of LctA is critical for dehydration activity[11b] and that disruption of a proposed helical
structure[73] within this C-terminal stretch by proline mutations strongly hampered the
dehydration efficiency. The leader peptides of class III lanthipeptides contain an I-L-D/E-L-
Q putative helix-forming motif near the N-terminus that is highly conserved. This
recognition motif has been shown to be essential for enzymatic production of
labyrinthopeptin A2 (Figure 11), while the C-terminal part of the leader has been proposed
to act as a spacer between the binding motif and the core sequence.[61] A length requirement
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between the proposed enzyme binding site on the leader peptide and residues in the core
peptide that can be modified by the PTM enzymes has also been observed for lacticin 481
and nisin.[68f, 74]
In other RiPP systems, truncation of the leader peptide of the lasso peptide MccJ25 showed
that only the eight C-terminal residues are important for producing the mature MccJ25 in E.
coli, whereas the 25 residues on the N-terminal portion are dispensable.[60] These
observations resemble the findings with the lanthipeptide lacticin 481 for which the N-
terminal 9 amino acids were not required for in vitro dehydration and cyclization.[11b] The
leader peptide of microcin B17 (Figure 4) is also believed to form a helical structure upon
binding to its synthetase.[62] The presence of the helix and several key hydrophobic residues
in the leader region are important for the enzyme to carry out the heterocyclization reaction
on the native core peptide[22b, 62] and artificial core peptides.[31b, 70e] The first modified
amino acid in the core peptide is separated from the end of the leader peptide by an
essential[70f] Gly-rich spacer peptide (Figure 4). Like the lanthipeptides discussed above, it
has been proposed that this linker is required to allow the core region to reach the active
site(s) of the PTM enzymes for modification. The importance of residues in the leader
peptide has also been investigated by alanine scanning mutagenesis for streptolysin S,
another linear azol(in)e containing peptide.[70e] These studies revealed TQV and FXXXB (B
= hydrophobic amino acid) motifs that are important for recognition similar to the findings
for microcin B17. A short helix in the leader peptide has also been proposed to be important
for recognition by the synthetase for heterocycle formation in cyanobactins,[70a, 70d] and the
leader peptides of microviridins contain a strictly conserved PFFARFL recognition sequence
that forms a putative helical structure that is important for lactone and lactam formation.[37d]
Biosynthetic enzymes in one pathway can recognize different parts of the substrate
peptides
An important point with respect to leader peptide recognition is that not all the PTM
enzymes need to recognize the same sequence of the leader peptide. Indeed, in cyanobactin
biosynthesis, the enzymes involved in cyclodehydration likely require the leader peptide
based on LAP biosynthesis,[62] whereas the enzymes that are responsible for head-to-tail
cyclization require the recognition sequences that are immediately flanking the core
peptides.[30, 32, 75] Similarly, mutagenesis studies have shown that the double Gly motif in
the leader peptide of the class II lanthipeptide lacticin 481 is essential for proteolytic
processing,[68c, 69b] but not for installation of lanthionine rings.[68d] Conversely, pull down
experiments have shown that both the dehydratase NisB and the cyclase NisC bind the
precursor peptide NisA, consistent with in vitro activity and binding data,[72a, 76] and
mutagenesis experiments suggest both enzymes recognize the FNLD box on their NisA
substrates.[68f, 72] Although these experiments show that the leader peptide is important for
binding to NisB,[72a] as discussed in the next section, it is likely that NisB also has affinity
for the core peptide.
Although both NisB and NisC recognize and bind the leader peptide, not all the enzymes
that require the presence of the leader peptide for in vivo activity need to actually bind to the
leader peptide themselves if they are part of a multi-enzyme complex. Indeed, many RiPP
PTM enzymes are part of such complexes.[15, 22b, 26, 37d, 77] In principle, only one of the
proteins in the complex needs to bind the leader peptide if the function of the leader peptide
is just to bring the core peptide in proximity to the active sites of the proteins in the
complex.
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Biosynthetic enzymes in different RiPP pathways can recognize similar leader peptides
Not only do multiple enzymes that carry out very different reactions during the biosynthetic
pathway to one particular RiPP recognize the same leader peptide as discussed in the
previous section, PTM enzymes that produce very different classes of RiPPs can use leader
peptides that are homologous. For instance, lanthipeptide synthetases, azoline
cyclodehydratases, and radical SAM enzymes all act on members of the nitrile hydratase-
like leader peptide (NHLP) family, as well as the nif11-like leader peptide family.[46, 78] The
NHLP and nif11 leader peptides are uncharacteristically long and display clear sequence
homology to the alpha subunit of the enzyme nitrile hydratase and the Nif11 nitrogen-fixing
proteins from cyanobacteria, respectively.[46b] As such, these leader peptides appear to have
been repurposed from enzymatic functions to allosteric regulation, the first clues of the
evolutionary origins of leader peptides.[46b] Along similar lines, leader peptides ending in
the double glycine motif with sequence homology to RiPP leader peptides are also found in
bacteriocins that do not undergo posttranslational modifications. Hence, the leader peptides
of these RiPP precursor peptides may have evolved from a role in secretion to include
additional roles in activating the enzymes involved in posttranslational modification.
Is the Core Peptide Recognized by the Biosynthetic Enzymes?
As discussed in previous sections, the RiPP biosynthetic enzymes display remarkable
plasticity with respect to processing variants of the core
peptides.[15-16, 31a, 35a, 52, 55, 70e, 74, 79] Particularly striking examples are the attachment of
entirely foreign sequences to lanthipeptide leader peptides that are dehydrated and cyclised
by their biosynthetic enzymes,[52, 69a] and natural combinatorial biosynthesis in which the
core peptides are hypervariable but the leader peptides or recognition sequences are highly
conserved.[31b, 78] These observations raised the question whether the PTM enzymes
recognize the core peptides at all. Recent studies in the lanthipeptide area suggest they
typically do. First, the observation that the biosynthetic enzymes can dehydrate the core
peptides in the absence of the leader peptide[56-58] can only be explained if the enzymes
have some affinity for the core peptide. Second, the observed activity when the leader
peptide is provided in trans, whether in vitro,[57] in vivo,[72b] or attached to the lanthionine
synthetase,[58] requires that the enzyme must have affinity for the core peptide.
It is informative to consider the challenges faced by the various posttranslational
modification enzymes with respect to core peptide recognition. Some enzymes such as the
Ser/Thr dehydratases in lanthipeptide biosynthesis or the Ser/Thr/Cys cyclodehydratases
involved in azol(in)e biosynthesis act on all or nearly all cognate amino acids in the core
peptides. Hence, the main challenge is which cognate amino acids are “skipped”.[74-75]
One possible explanation for modification of most but not all Ser/Thr and/or Cys residues is
that the enzymes display a strict order in which they catalyze their iterative chemical
reactions, such that certain residues can be “protected” from posttranslational modification
(e.g. because a ring is formed around or next to it it or because a D-stereocenter is
introduced on a flanking residue). Indeed, several leader peptide dependent reactions in
RiPP biosynthesis have been shown to display directionality. This was first shown for the
heterocylization for microcin B17, which takes place from the N-terminus of the core
peptide to the C-terminus.[80] Similarly, the dehydration and cyclization reactions during the
biosynthesis of the class I lantibiotic nisin and the class II lantibiotics lacticin 481 and
haloduracin move from the N-terminus of the core peptide towards the C-terminus.[81]
These studies also suggest that dehydration and cyclizations may be tightly coupled
alternating activities. Conversely, for the class III lanthipeptides labyrinthopeptin A2 and
catenulipeptin, the synthetases display a C- to N-terminal processing mode.[82] A
predominantly C-to-N terminal directionality has also been reported for the LAP
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plantazolicin.[79o] For all investigated examples, the enzymatic reactions that are directional
are not processive, but rather distributive.[79o, 80, 81b, 82] That is, the enzymes release the
intermediates after each enzymatic reaction rather than keeping them bound, at least in vitro.
These observations are in keeping with the moderate affinities that have been reported for
most RiPP enzymes for their substrate peptides,[72a, 76b] which in turn is beneficial to avoid
product inhibition. Another example of specific order of biosynthetic reactions is found for
the microviridins where the order appears not to be determined as much by directionality as
by chemoselectivity, with the ester bonds being formed before the amide bonds. Although
many of these enzymatic processes display overall directionality in vitro, most are not
strictly directional as two residues that are localized close in sequence often are not strongly
differentiated. It is possible that in vivo the directionality may be tighter. First, other proteins
that make up multi-enzyme complexes but that are absent in in vitro studies could provide
additional control. Secondly, in vitro reactions have typically been conducted with the
precursor peptide in excess over the biosynthetic enzymes whereas in vivo it is likely that
this is not the case. Excess substrate can compete with substrates that are being modified,
potentially leading to disruption of strict directionality.
How can one enzyme make rings of different sizes, sequences, and even stereochemistry?
Crosslinking enzymes have considerably bigger challenges to overcome, as they typically
generate a single ring topology when many different topologies are possible. For instance,
consider the cyclization process for nisin (Figure 2B). The dehydrated NisA peptide contains
five Cys nucleophiles and eight dehydro amino acid electrophiles (three Dha, five Dhb).
Statistically, the number of constitutional isomers that can be generated by a Michael type
cyclization process that lacks regio- and chemoselectivity would be 6,720. Moreover, if
taking into account all of the possible stereoisomers that can be formed during the Michael
addition, this number would be even greater (the exact number depends on whether Lan or
MeLan products are formed, but would be at least 8.6×105). However, NisC generates a
single product out of all these potential structures. Although the control over ring topology is
most relevant to the lanthipeptides, similar considerations are also in play for other
crosslinking reactions such as thioether formation in sactipeptides or lactone/lactam
formation in microviridins.
The control over site selectivity is an astounding feat considering that the crosslinks formed
by one enzyme often involve very different amino acid sequences and ring sizes (e.g. NisC
makes rings that range from four amino acids to seven amino acids with very different
sequences, Figure 2B). How one active site of defined size could actively “enforce”
formation of these very different rings is difficult to comprehend. Moreover, the shape of the
substrate peptide is changing dramatically with each cyclization, especially for RiPPs with
overlapping rings (eg lacticin 481, Figure 11), which again is difficult to reconcile with a
single, well-defined active site. Another puzzling system is the class II lanthipeptide
synthetase ProcM. This enzyme is produced by a Prochlorococcus strain that encodes only
one lanthipeptide synthetase but no less than 29 different substrate peptides on its
genome.[78] The leader peptides of these substrates are highly homologous, but the core
peptides are highly diverse. ProcM converts these core peptides into a library of polycyclic
peptides with high structural diversity (e.g. Figure 12).[83]
These observations prompt us to speculate that perhaps the core peptides themselves
determine the outcome of the cyclization process. Additional observations that point in this
direction are the observed phylogenomic divergence of cyclase enzymes that generate very
similar ring topologies,[84] and the recent remarkable observation that rings formed from a
DhxDhxXxxXxxCys motif (Dhx = Dha or Dhb; Xxx is any amino acid) in the substrate
peptides for three different lanthipeptides have different stereochemistry from the canonical
(2S, 6R) and (2S, 3S, 6R) configurations. During the cyclization process of these
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lanthipeptides (haloduracin β and both peptides of cytolysin, Figures 11 and 12), a single
synthetase catalyzes ring formation with both the canonical stereochemistry, resulting from
attack of the Cys onto the Si face of the Dhx residue in an overall anti addition, as well as
alternative stereochemistry, resulting from overall anti addition in which the Cys attacks the
Re face of the Dhx residue. Again, it is difficult to envision how an enzyme active site could
actively enforce both types of geometries in a well defined pocket.
Instead, we propose that the enzyme surface may have different patches of hydrophobic and/
or charged residues that are complementary to the different rings that the enzyme makes. In
this model, a highly promiscuous enzyme like ProcM has not evolved to actively favor the
formation of specific rings but instead makes rings that the substrate inherently favors.
Unless certain ring topologies are energetically very highly favored, this model suggests
ProcM may generate multiple products from one substrate peptide, something that needs to
be investigated in more detail. The predecessors of the modern enzymes such as NisC,
which are now very specific in the rings they make, initially may also have made rings
determined by the sequence of the precursor peptides. Once one of the products conferred an
evolutionary advantage upon the producing strain, any enzyme that would favor the
formation of this product would be selected for. In our model, this could mean that the
surface of the enzyme near the zinc ion that activates the substrate[76a, 85] would start to
evolve such that it is most complementary to the residues in the rings found in the product
that confers the advantage. The observation that one enzyme can make rings of different
sizes and different stereochemistry can be explained by this model by having different
complementary patches on the enzyme for the different rings of the bioactive product. The
alternative stereochemistry observed for cytolysin and haloduracin would then be the result
of the original propensity of a peptide containing two consecutive Dhx residues to attain a
different conformation that presents the opposite face of the alkene to the zinc-bound Cys
nucleophile. An alternative, or complementary, model to select for the bioactive topology
during evolution could involve the development of alternating dehydratase and cyclase
activities that could favor the bioactive ring topology by preventing alternative ring patterns.
Much research will be needed to test this mechanistic hypothesis, but some data already is
available. Early model studies of the Michael-type additions that generate the thioether
crosslinks in lanthipeptides concluded that indeed, the peptides have a propensity to form
the same stereochemical products in the absence of any enzymes as is observed for authentic
lanthipeptides when individual rings are studied.[86] However, when multiple dehydro
amino acids and cysteines are present, a biomimetic approach did not provide the desired
ring topology for the one case that has been investigated (the nisin A and B rings).[87]
Hence, the NisC cyclase must in some way guide ring formation. It is worth noting that
these model studies were carried out before it was known that a Zn2+ ion is used in
lanthionine cyclases to promote the Michael-type additions,[76a, 85] and that it may be that
base-catalysed conjugate addition is not a good mimic for metal-promoted cyclization.
Support for the notion that the precursor peptide may have an inherent propensity to form
specific ring structures is provided by various studies in which chimeric peptides were
constructed made up of a leader peptide of one lanthipeptide and the core peptide of a
different lanthipeptide. When a chimera consisting of the subtilin leader and nisin core
peptides was expressed in a subtilin producing Bacillus strain, a fully processed product was
observed.[88] Similarly, when a chimera containing a subtilin leader and nisin core peptide
was expressed in a nisin producing Lactococcus strain the core peptide was processed.[89]
These early studies support the idea that the core peptides contain the information for correct
ring formation, but the subtilin and nisin ring topologies are essentially identical (Figures 2
and 12), and hence it is still possible that the NisC cyclase recognized the subtilin core
peptide and vice versa. The same argument can be made for the observed in vitro production
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of nukacin ISK-1 by the lacticin 481 synthetase LctM from a chimeric substrate consisting
of the lacticin 481 leader peptide and the nukacin core peptide,[68d] because lacticin 481 and
nukacin ISK-1 have the same ring topology. However, more recent studies have expanded
the use of chimeric peptides. For instance, a chimera of the nisin leader peptide and the core
peptide of a class II lantibiotic pneumococcin that has no sequence homology to nisin could
be modified and secreted as a bioactive product by the class I nisin machinery.[90] Similarly,
a NisA-ElxA chimeric peptide containing the core peptide of epilancin 15X fused to the C-
terminus of the nisin leader was processed by the nisin dehydratase NisB and cyclase NisC
in E. coli.[84]
As mentioned above, ProcM has very relaxed substrate specificity and processes 29 very
diverse core peptides, suggesting it does not enforce any specific topology. We reasoned that
ProcM may therefore be the best available biosynthetic enzyme to test the idea that the core
peptide determines the site selectivity of cyclization. The lacticin 481 core sequence is not
found in the 29 core peptides that ProcM acts on. Therefore, we probed whether ProcM, an
enzyme from a marine cyanobacterium, could make lacticin 481, a compound produced by a
lactic acid bacterium; LctM and ProcM have just 22% sequence identity. When a chimeric
peptide consisting of the ProcA leader peptide and lacticin 481 core peptide was co-
expressed with ProcM, the resulting product after removal of the leader peptide indeed
contained a significant amount of lacticin 481.[84] Therefore, for certain scaffolds, the ring
topology of the final lanthipeptide is not just determined by the synthetase, but also by the
sequence of the substrate. Although any tests of this proposal have been limited thus far to
lanthipeptides, it is worth noting that sactipeptides have a very distinct hairpin structure and
it is possible that this secondary structure is already present before the thioether crosslinks
are formed. Indeed, it is has been proposed that the thioether bridges are installed via a
zipper mechanism, in which the first thioether bond formation aids the formation of the
second thioether bridge.[43, 91] This mechanism would be facilitated by an inherent
propensity of the substrate to already attain a conformation that brings the cysteine residues
close to their partners to which they become crosslinked. However, the precursor peptide to
the lasso peptide MccJ25 does not appear to attain a conformation that resembles the lasso
fold in the absence of the biosynthetic enzymes.[92] Hence, not all RiPP precursor peptides
need to have an intrinsic propensity to exist in conformations that are close that those found
in the final crosslinked product.
Summary
The leader peptide is important for most but not all biosynthetic enzymes. For those
enzymes that are activated by binding of the leader peptide, we suggest based on the
available information that leader peptide binding functions as an allosteric effector that
changes the distribution of enzyme populations towards the active conformation. At present,
the details of the molecular recognition of the leader peptide by the biosynthetic enzymes
are still largely unknown. Indirect evidence suggests that the enzymes recognize secondary
structure rather than specific residues given the high tolerance that has been demonstrated
with respect to leader peptide mutations. It is possible that this is a built-in safety feature to
allow high evolvability of the core peptide sequence without placing too much of a
restriction on maintaining the sequence of the leader peptide. Recent studies have also
demonstrated that the enzymes clearly must recognize the core peptides of their substrates,
and possibly that the core peptides may in part determine the ring topology and
stereochemistry of the final products.
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General biosynthetic pathway of RiPPs. RS = recognition sequence.
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(A) Biosynthesis of nisin A. (B) Generation of (Me)Lan and labionin motifs.
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(A) Three classes of lasso peptides. Residues involved in the macrolactam are shown in red.
(B) Structure of microcin J25 as a representative lasso peptide. (C) Righthanded
conformation of lasso peptides.
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(A) Biosynthesis of microcin B17 as a representative LAP. (B) Generation of oxazol(in)e
and thiazol(in)e motifs.
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. Proposed biosynthesis of patellamides A and C. The precursor peptide contains an N-
terminal leader peptide and two core peptide cassettes. In each cassette, the core peptide
sequence is sandwiched between two recognition sequences (purple/green).
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Structure of bottromycin A2.
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Structure of microviridin B.
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Proposed biosynthesis of subtilosin A.
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Structures of polytheonamide A and B. The two peptides differ by the configuration of the
sulfoxide moiety. Epimerizations are shown in blue, methylation is shown in red, and
hydroxylation is shown in purple.
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Proposed role of the leader peptide in activating their biosynthetic enzymes. The leader
peptide is shown in red. The core peptide is shown in blue. The potential pseudosubstrate
domain of the synthetase is shown in purple.
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Some representative lanthipeptides. The same shorthand notation is used as in Fig. 2.
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Lanthipeptide structures that have been used for studies investigating the role of the core
peptide. The same shorthand notation is used as in Figure 2. (Me)Lan residues with unusual
stereochemistry are shown in pink.
Yang and van der Donk Page 31
Chemistry. Author manuscript; available in PMC 2014 June 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
